BioStrand, a Belgian startup that is advancing technology for analyzing genetic data, raised €2m in funding.
K-E made the investment.
The company intends to use the funds to commercialize its platform.
Created in February 2019 by Dr Dirk van Hyfte, CTO, and led by Dr Ingrid Brands, CEO, BioStrand is advancing technology for analyzing genetic data, which will drive innovation in the fields of precision medicine, biotechnology and agriculture. Over the past seven years, Dr. Dirk van Hyfte and Dr. Ingrid Brands have developed the technology to detect analogies and genetic variations. In addition to the funding, Stijn Bijnens, CEO of Cegeka, will sit on the Board of Directors of BioStrand.